Eric Crombez - Mar 1, 2025 Form 4 Insider Report for Ultragenyx Pharmaceutical Inc. (RARE)

Role: EVP and Chief Medical Officer
Signature: /s/ Karah Parschauer, attorney-in-fact
Stock symbol: RARE
Transactions as of: Mar 1, 2025
Transactions value $: -$376,585
Form type: 4
Date filed: 3/4/2025, 08:16 PM
Previous filing: Feb 3, 2025
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	RARE	Common Stock	Award	$0	+16.8K	+34.72%	$0.00	65.2K	Mar 1, 2025	Direct	F1
transaction	RARE	Common Stock	Award	$0	+15K	+22.95%	$0.00	80.2K	Mar 1, 2025	Direct	F2
transaction	RARE	Common Stock	Sale	-$377K	-8.95K	-11.06%	$42.10	71.9K	Mar 3, 2025	Direct	F3, F4, F5, F6

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	RARE	Stock Ooption (Right to Buy)	Award	$0	+30.2K		$0.00	30.2K	Mar 1, 2025	Common Stock	30.2K	$42.92	Direct	F7

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Award of Restricted Stock Units ("RSUs") under the Company's 2023 Incentive Plan. The RSUs shall vest with respect to 1/4th of the underlying shares on each anniversary of the grant date, such that the RSUs are fully vested on the fourth anniversary of the grant date
F2	Represents shares of common stock which previously granted performance stock units were converted on March 1, 2025 upon certification of the performance metric.
F3	Represents shares sold to pay required tax withholdings due to the vesting of RSUs.
F4	The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $41.77 to $42.90 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
F5	Includes previously reported shares of common stock underlying RSUs granted to the Reporting Person, which are subject to certain vesting conditions.
F6	Includes 652 shares acquired on April 30, 2024 and October 31, 2024 under the Company's Amended and Restated Employee Stock Purchase Plan
F7	On the first anniversary of the grant date of the option (the "Option Anniversary Date"), 1/4th of the shares initially subject to the option shall vest; thereafter, 1/48th of the shares initially subject to the option shall vest on each month as measured from the Option Anniversary Date.